Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2025; 17(9): 109965
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109965
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109965
Implications of gut microbiota in hepatic and pancreatic diseases: Gut-liver-pancreas axis
Maya Magdy Abdelwahab, Ahmad S Ghattas, Faculty of Medicine, Helwan University, Cairo 11795, Al Qāhirah, Egypt
Ahmed Tawheed, Department of Gastroenterology, Al Emadi Hospital, Doha 50000, Qatar
Author contributions: Tawheed A designed and revised the manuscript; Abdelwahab MM and Ghattas AS wrote the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmed Tawheed, Department of Gastroenterology, Al Emadi Hospital, D Ring Road, Doha 50000, Qatar. atawheed1990@gmail.com
Received: May 27, 2025
Revised: June 30, 2025
Accepted: August 12, 2025
Published online: September 27, 2025
Processing time: 122 Days and 2.9 Hours
Revised: June 30, 2025
Accepted: August 12, 2025
Published online: September 27, 2025
Processing time: 122 Days and 2.9 Hours
Core Tip
Core Tip: This editorial highlights the central role of gut microbiota in regulating the gut-liver-pancreas axis, a dynamic network critical for metabolic and immune homeostasis. Dysbiosis-driven disruptions-via microbial metabolites, barrier dysfunction, and immune imbalance-underlie the pathogenesis of liver and pancreatic diseases. While gut-liver interactions are well studied, gut-pancreas crosstalk remains underexplored. We emphasize emerging biomarkers, microbial-based therapies, and the urgent need for longitudinal studies and metabolomic profiling to translate microbiome science into precision diagnostics and treatments for hepatopancreatic disorders.